NVS/MNTA and MYL/Natco are the only ANDA filers for Copaxone, and I doubt there will be any others.
MYL is merely the US regulatory and distribution arm for the Copaxone knockoff Natco sells in India. I don’t think this drug stands a chance of getting FDA approval as a generic version of Copaxone.
Market Data 
Markets 
AI
